{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 155 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 12.2', 'A per protocol analysis set will be used as an', 'Specification that the per', 'Trial analysis sets', 'efficacy subset for the analysis of the primary', 'protocol analysis set will', 'endpoints up to Week 16 (visit 12)', 'be used for analysis of the', 'primary endpoints only.', 'The per protocol analysis set will be defined', 'To predefine the criteria', 'by excluding subjects from the full analysis set', 'leading to exclusion from', 'for whom any of the following conditions', 'the per protocol analysis', 'apply:', 'set, rather than deferring', 'receive no treatment with the IMP.', 'until a blinded review of', 'the data.', 'provide no efficacy data assessment of', 'IGA or EASI following start of', 'treatment.', 'are known to have taken the wrong IMP', 'throughout the initial treatment period of', 'the trial.', 'do not fulfil all the disease defining', 'inclusion criterion (i.e. inclusion criterion', 'no.3) inclusion criteria no. 3, 6, 7 and 8.', 'Further exclusion of subjects or subject data', 'will be decided upon after a blinded review of', 'the data, reviewing all the remaining in and', 'exclusion criteria, but focusing on concomitant', 'medication that may affect AD and also', 'considering compliance adherence and', 'violations of visit windows.', 'Section 12.3.1', 'For all randomised subjects the reasons for', 'Clarification that reasons', 'Disposition of', 'permanent discontinuation of IMP and for', 'for permanent', 'subjects', 'leaving the trial in the initial treatment period', 'discontinuation of IMP', 'will be presented by last visit attended and by', 'will be presented.', 'treatment group. For the subjects in the', 'maintenance safety analysis set, the reasons for', 'permanent discontinuation of IMP and for', 'leaving the trial or treatment arm will be', 'presented by last visit attended and by the', 'assigned treatment group at Week 16. For the', 'subjects in the open-label safety analysis set,', 'the reasons for permanent discontinuation of', 'IMP and for leaving the trial will be presented', 'by last visit attended.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 156 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 12.3.2', 'The presentations will be overall and by', 'Baseline disease severity', 'Demographics and', 'treatment group. Presentations of age, sex,', 'added since this is also a', 'other baseline', 'ethnicity, race, baseline disease severity, and', 'stratification factor, in', 'characteristics', 'Worst Daily Pruritus NRS weekly average at', 'addition to region.', 'baseline will also be given by region and by', 'baseline disease severity (IGA 3 or 4).', 'Section 12.3.5.1', 'This section has been amended to implement', 'To pre-specify the method', 'Analysis of primary', 'the concept of estimands together with the', 'of handling missing data.', 'endpoints', 'pre-specification of sensitivity analyses. The', 'primary analyses of the primary endpoints are', 'unchanged compared to the statistical analysis', 'plan provided in the original protocol dated', '03-Mar-2017.', 'Section 12.3.5.2', 'This section has been amended to implement', 'To pre-specify the method', 'Analysis of', 'the concept of estimands together with the', 'of handling missing data.', 'secondary endpoints', 'pre-specification of sensitivity analyses. The', 'primary analyses of the secondary endpoints', 'are unchanged compared to the statistical', 'analysis plan provided in the original protocol', 'dated 03-Mar-2017.', 'Section 12.3.5.3', 'This section has been updated to describe the', 'To describe the statistical', 'Analysis of', 'statistical analysis of the additional secondary', 'analysis of new endpoint.', 'additional secondary', 'endpoint EASI90.', 'endpoints', 'Section 12.3.5.4.1', 'This is a new section describing the statistical', 'To describe the statistical', 'Efficacy over time', 'analysis of the 6 new other endpoints which', 'analysis of new endpoints.', 'address efficacy over time.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}